Figure 1

Reduction in risk of heart failure. Reduction in risk of heart failure shown for each 1% increase in ejection fraction for each baseline ejection fraction stratum of patients (blue- normal baseline EF; red- low baseline EF). The risk reduction associated with the increases in ejection fraction from 2 randomized controlled trials of deferiprone are shown, with the target drug doses[8, 9]. The risk reductions associated with improvements in EF of 2-3% are substantial and clinically meaningful in both groups.